Table 1.
Involvement of non-measurable lesions in Japanese clinical trials
| Trial [Ref no.] | Treatment | Response rate (%) | Median overall survival (M) | Frequency of non-measurable lesions | |||
|---|---|---|---|---|---|---|---|
| Total population | Measurable | Non-measurable | (%) | Total | |||
| JCO9912 [28] | 5-FU | 9 | 10.8 | N/A | N/A | 37.2 % (87/234) | 33.0 % (232/704) |
| CPT-CDDP | 38 | 12.3 | 32.2 % (76/236) | ||||
| S-1 | 28 | 11.4 | 29.4 % (69/234) | ||||
| SPIRITS [3] | S-1 | 31 | 11.0 | N/A | N/A | 24 % (36/150) | 29.2 % (87/298) |
| S-1/CDDP | 54 | 13.0 | 34 % (51/148) | ||||
| TOP-002 [29] | S-1 | 26.9 | 10.5 | N/A | N/A | N/A | 33.3 % (105/315) |
| S-1/CPT | 41.5 | 12.8 | N/A | ||||
| START [5] | S-1 | 26.8 | 10.8 | 10.3 | 12.0 | 40.8 % (131/321) | 39.3 % (250/635 |
| S-1/DTX | 38.8 | 12.5 | 11.7 | 17.9 | 37.9 % (119/314) | ||
| SOS [30] | SP5 | 50 | 13.9 | N/A | N/A | 37 % (113/309) | N/A |
| SP3 | 60 | 14.1 | 39 % (120/306) | ||||
| G-SOX [31] | SP | 52.2 | 13.1 | N/A | N/A | 19.8 % (64/324) | 19.5 % (125/642) |
| SOX | 55.7 | 14.1 | 19.2 % (25/294) | ||||
| ToGA [7] | XP | 35 | 11.1 | N/A | N/A | 11.3 % (33/290) | 9.9 % (58/584) |
| XP + Tmab | 47 | 13.8 | 8.5 % (25/294) | ||||
| AVAGAST [32] | XP | 37.4 | 10.1 | N/A | N/A | 23.2 % (90/387) | 21.4 % (166/774) |
| XP + Bev | 46.0 | 12.1 | 19.6 % (76/387) | ||||